

Supplemental information

**Poly(GR) interacts with key stress
granule factors promoting its assembly
into cytoplasmic inclusions**

Jinyoung Park, Yanwei Wu, Wei Shao, Tania F. Gendron, Sophie J.F. van der Spek, Grigorii Sultanakhmetov, Avik Basu, Paula Castellanos Otero, Caroline J. Jones, Karen Jansen-West, Lillian M. Daughrity, Sadhna Phanse, Giulia del Rosso, Jimei Tong, Monica Castanedes-Casey, Lulu Jiang, Jenna Libera, Björn Oskarsson, Dennis W. Dickson, David W. Sanders, Clifford P. Brangwynne, Andrew Emili, Benjamin Wolozin, Leonard Petrucelli, and Yong-Jie Zhang











Figure S1. G3BP1/2 is crucial for poly(GR) inclusion formation, related to Figure 1. (A) Double-immunofluorescence staining for G3BP1 and TIA-1 in U2OS WT and G3BP1/2 knockout (GG KO) cells expressing GFP-(GR)₁₀₀ 48 h post-transfection. White arrows indicate cytoplasmic poly(GR) inclusions and yellow arrows indicate nucleolar poly(GR) accumulation. Scale bars, 5 μ m. (B) Double-immunofluorescence staining for G3BP1 and ataxin 2 in WT and GG KO U2OS cells expressing GFP-(GA)₁₀₀ 48 h post-transfection. Scale bars, 5 μ m. (C) Quantification of the percentage of GFP-positive cells containing poly(GA) inclusions in WT and GG KO U2OS cells (n = 3 independent experiments). (D) Schematic of G3BP1 protein domains. (E) Immunoblot analysis using the indicated antibodies in GG KO cells stably expressing mCherry-G3BP1 species to confirm expression of mCherry-G3BP1 proteins. GAPDH was used as control for protein loading. (F) Immunofluorescence staining for ataxin 2 in GG KO U2OS cells stably expressing mCherry-G3BP1 species under basal conditions. Scale bars, 5 μ m. (G, H) Immunofluorescence staining for eIF3 η (G) or TIA-1 (H) in GG KO U2OS cells expressing GFP-(GR)₁₀₀ and stably expressing mCherry-G3BP1 species. Scale bars, 5 μ m. Data shown as mean \pm SEM, ns (not significant) $P = 0.8337$, unpaired two-tailed t-test.





Figure S2. Time-dependent increase of cytoplasmic poly(GR) inclusions and enrichment of m6A modified RNAs in poly(GR) inclusions, related to Figure 2. (A) Double-immunofluorescence staining for YTHDF1 and G3BP1 in HEK293T cells expressing GFP-(GR)₁₀₀ for 24 or 48 h. White arrows indicate cytoplasmic poly(GR) inclusions and yellow arrows indicate nucleolar poly(GR) accumulation. Scale bars, 10 μm. (B) Quantification of the percentage of cells containing poly(GR) inclusions in GFP-(GR)₁₀₀-expressing HEK293T cells (n = 3 independent experiments). (C) Quantification of the size of poly(GR) inclusions in GFP-(GR)₁₀₀-expressing HEK293T cells (n = 3 independent experiments). (D) Double-immunofluorescence staining for GFP and m6A in HEK293T cells expressing GFP-(GR)₁₀₀ for 24 or 48 h; n = 3 independent experiments, scale bars, 2 μm. (E) Quantification of the relative ratio of oligo(dT) intensity [poly(GR) inclusions/Total] in GFP-(GR)₁₀₀-expressing HEK293T cells (n = 3 independent experiments). Data shown as mean ± SEM. In (B) *** $P = 0.0002$, unpaired two-tailed t-test. In (C), **** $P < 0.0001$, unpaired two-tailed t-test. In (E), * $P = 0.0322$, unpaired two-tailed t-test.






Figure S3. Modulating YTHDF proteins and m6A-modified RNAs does not affect poly(GR) expression, related to Figure 3. (A) Immunoblots of YTHDF1 or YTHDF3 in YTHDF1/3-depleted HEK293T cells expressing GFP or GFP-(GR)₁₀₀. GAPDH was used as a loading control. (B) MSD immunoassay for poly(GR) in YTHDF1/3-depleted HEK293T cells expressing GFP or GFP-(GR)₁₀₀ (n = 3 independent experiments). (C) Double-immunofluorescence staining for YTHDF1 and G3BP1 in YTHDF1/3-depleted HEK293T cells expressing GFP-(GA)₁₀₀ 48 h post-transfection. Scale bars, 10 μm . (D) Quantification of the percentage of GFP-positive cells containing poly(GA) inclusions in YTHDF1/3-depleted HEK293T cells expressing GFP-(GA)₁₀₀ (n = 3 independent experiments). (E) Quantification of the size of poly(GA) inclusions in YTHDF1/3-depleted HEK293T cells expressing siing GFP-(GA)₁₀₀ (n = 3 independent experiments). (F) Immunoblots of V5 in GFP or GFP-(GR)₁₀₀ overexpressing HEK293T cells co-expressing GFP or GFP-(GR)₁₀₀ and either tagBFP-V5 or tagBFP/V5 tagged wild-type YTHDF1 (tagBFP-

DF1-V5). GAPDH was used as a loading control. (G) MSD immunoassay for poly(GR) in GFP or GFP-(GR)₁₀₀ overexpressing HEK293T cells co-expressing either tagBFP-V5 or tagBFP-DF1-V5. (n = 3 independent experiments). (H) Immunoblot for ALKBH5, YTHDF1 and YTHDF3 in ALKBH5-depleted HEK293T cells expressing either GFP or GFP-(GR)₁₀₀. GAPDH was used for a loading control. (I) m6A-modified RNA quantification using ELISA in ALKBH5-depleted HEK293T cells expressing either GFP or GFP-(GR)₁₀₀ (n = 3 independent experiments). (J) Double-immunofluorescence staining for GFP and m6A in ALKBH5-depleted HEK293T cells expressing GFP-(GR)₁₀₀ 24 h post-transfection. Scale bars, 2 μ m. (K) Quantification of the intensity for m6A in ALKBH5-depleted HEK293T cells expressing GFP-(GR)₁₀₀ 24 h post-transfection (n = 3 independent experiments). (L) MSD immunoassay for poly(GR) in ALKBH5-depleted HEK293T cells expressing either GFP or GFP-(GR)₁₀₀ (n = 3 independent experiments). (M) Double-immunofluorescence staining for YTHDF1 and G3BP1 in ALKBH5-depleted HEK293T cells expressing GFP-(GA)₁₀₀ 24 h post-transfection. Scale bars, 10 μ m. (N) Quantification of the percentage of GFP-positive cells containing poly(GA) inclusions in ALKBH5-depleted HEK293T cells expressing GFP-(GA)₁₀₀ (n = 3 independent experiments). (O) Quantification of the size of poly(GA) inclusions in ALKBH5-depleted HEK293T cells expressing GFP-(GA)₁₀₀ (n = 3 independent experiments). (P) Immunoblots for Flag, YTHDF1 and YTHDF3 in Flag-ALKBH5-expressing HEK293T cells co-expressing either GFP or GFP-(GR)₁₀₀. GAPDH was used as a loading control. (Q) m6A-modified RNA quantification in Flag-ALKBH5-expressing HEK293T cells co-expressing either GFP or GFP-(GR)₁₀₀ by ELISA (n = 4 independent experiments). (R) Triple-immunofluorescence staining for GFP, Flag and m6A in Flag-ALKBH5-overexpressing HEK293T cells co-expressing GFP-(GR)₁₀₀ 48 h post-transfection. Scale bars, 2 μ m. (S) Quantification of the intensity for m6A in Flag-ALKBH5 overexpressing HEK293T cells co-expressing GFP-(GR)₁₀₀ 48 h post-transfection (n = 3 independent experiments). (T) MSD immunoassay for poly(GR) in Flag-ALKBH5 expressing HEK293T cells co-expressing either GFP or GFP-(GR)₁₀₀ (n = 4 independent experiments). (U) Immunoblots for ALKBH5, YTHDF1 and YTHDF3 in ALKBH5-depleted and/or YTHDF1/3-depleted HEK293T cells overexpressing either GFP or GFP-(GR)₁₀₀. GAPDH was used for a loading control. (V) m6A-modified RNA quantification in ALKBH5-depleted and/or YTHDF1/3-depleted HEK293T cells overexpressing GFP-(GR)₁₀₀ by ELISA (n = 3 independent experiments). (W) MSD immunoassay for poly(GR) in ALKBH5-depleted and/or YTHDF1/3-depleted HEK293T cells overexpressing GFP-(GR)₁₀₀ (n = 3 independent experiments). Data shown as mean \pm SEM. In (B), ns (not significant) $P = 0.8931$, unpaired two-tailed t-test. In (E), ns $P = 0.8497$, unpaired two-tailed t-test. In (G), ns $P = 0.1877$, unpaired two-tailed t-test. In (I), *** (left to right) $P = 0.0009$, and $P = 0.0006$, one-way ANOVA. Tukey's post hoc analysis. In (K), * $P = 0.0318$, unpaired two-tailed t-test. In (L), ns $P = 0.9962$, unpaired two-tailed t-test. In (O), ns $P = 0.8128$, unpaired two-tailed t-test. In (Q), ** (left to right) $P = 0.0070$ and $P = 0.0049$, one-way ANOVA, Tukey's post hoc analysis. In (S), ** $P = 0.0016$, unpaired two-tailed t-test. In (T), ns $P = 0.6359$, unpaired two-tailed t-test. In (V), ** (left to right) $P = 0.0098$ and $P = 0.0038$; ns (left to right) $P = 0.4731$ and

$P = 0.1065$, one-way ANOVA, Tukey's post hoc analysis. In (W), ns (left to right) $P = 0.9714$, $P = 0.6208$, and $P = 0.7507$, one-way ANOVA, Tukey's post hoc analysis.




Figure S4. m6A modified RNAs facilitate mRNA incorporation in poly(GR) inclusions, related to Figure 4. (A) Immunofluorescence staining for oligo(dT) in ALKBH5-depleted HEK293T cells expressing GFP-(GR)₁₀₀ 24 h post-transfection. Scale bars, 2 μ m. (B) Quantification of the relative ratio of oligo(dT) intensity [poly(GR) inclusions/Total] in ALKBH5-depleted HEK293T cells expressing GFP-(GR)₁₀₀ (n = 3 independent experiments). (C) Double-immunofluorescence staining for Flag and oligo(dT) in Flag-ALKBH5 and GFP-(GR)₁₀₀ co-expressing HEK293T cells 48 h post-transfection. Scale bars, 2 μ m. (D) Quantification of the ratio of oligo(dT) intensity [poly(GR) inclusions/Total] in HEK293T GFP-(GR)₁₀₀-expressing cells transduced or not to express Flag-ALKBH5 (n = 3 independent experiments). Data shown as mean \pm SEM. In (B), * $P = 0.0213$, unpaired two-tailed t-test. In (D), * $P = 0.0211$, unpaired two-tailed t-test.

Table S1. Characteristics of patients with c9FTLD, related to STAR Methods.

Case #	Pathological Diagnosis	Gender	Age at Onset	Age at Death	Disease Duration	<i>C9orf72</i> repeat expansion
1	FTLD	M	NA	63.74	NA	Yes
2	FTLD	M	72.19	76.19	4	Yes
3	FTLD	M	58.51	62.51	4	Yes
4	FTLD	F	60.36	61.36	1	Yes
5	FTLD	F	57.21	69.21	12	Yes
6	FTLD	F	59.29	70.29	11	Yes

FTLD, frontotemporal lobar degeneration

Table S2. Primers for site-directed mutagenesis of YTHDF1, related to STAR Methods.

Primers	Sequence
Forward	5'-TAGTACTCGCTGAGGGTGAAC-3'
Reverse	5'-CATGGCCTTCCGTGTTTCCTA-3'